Lucid Capital initiated coverage of Tiziana Life Sciences (TLSA) with a Buy rating and $8 price target Tiziana is developing an intranasal antibody for numerous central nervous system conditions, the analyst tells investors in a research note. The firm believes the company is building a neurological franchise with foralumab that could be analogous to AbbVie’s Humira.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSA:
- Tiziana Life Sciences Unveils Promising Alzheimer’s Treatment Findings
- Tiziana Life announces immunologic analysis of nasal foralumab in AD patients
- Tiziana Life Sciences Expands Phase 2 MS Trial with New Site
- Tiziana Life Sciences expands Phase 2 intranasal foralumab trial with dosing
- Tiziana Life Sciences to Present Intranasal Foralumab Findings at Bio International Convention